Sex Differences in Obesity and Its Treatment
Authors:
- 18 March 2025
- journal article
- review article
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 27 (5) , 278-285
Abstract
Purpose of Review Researchers and clinicians have increasingly recognized the importance of investigating and considering sex differences in obesity treatment. In this narrative review, we first summarized sex differences in select obesity-related conditions that have been the focus of studies of second-generation anti-obesity medications (i.e., semaglutide and tirzepatide) including type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and heart failure. We next described sex differences related to obesity treatments with a focus on the second-generation anti-obesity medications, semaglutide and tirzepatide. Recent Findings Type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and heart failure demonstrated sex-specific pathways influenced by factors such as hormones and body composition. Lifestyle modification, on average, resulted in larger weight losses in males. In contrast, second-generation AOMs produced higher mean weight losses among females. Females reported more adverse events (e.g., nausea, vomiting) with second-generation anti-obesity medications. The few studies that have performed analyses of changes in obesity-related comorbidities stratified by sex have shown consistent improvements between males and females in heart failure and cardiovascular outcomes. Summary Studies are needed to evaluate the effect of sex on the efficacy of anti-obesity medications including on mental health, investigate the mechanisms underlying these effects, and develop interventions to improve the availability and access of these medications.Keywords
Funding Information
- National Institute of Nursing Research (R56NR020466)
This publication has 86 references indexed in Scilit:
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Sex differences in response to lifestyle intervention among children and adolescents: Systematic review and meta‐analysisObesity, 2023
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development programObesity, 2022
- Prevalence Trends of Site‐Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019Arthritis & Rheumatology, 2022
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5Obesity, 2020
- Reoperations After Bariatric Surgery in 26 Years of Follow-up of the Swedish Obese Subjects StudyJAMA Surgery, 2019
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk FactorsJAMA, 2016
- Longitudinal Study of Moderate Weight Change and Sleep-Disordered BreathingJAMA, 2000